![](/img/cover-not-exists.png)
1006 The anti-IGF-IR antibody figitumumab (CP-751,871) is active in patients with lung adenocarcinoma undergoing epithelial-tomesenchymal transition
A. Gualberto, M.L. Hixon, M.P. Dolled-Filhart, J. Chistensen, D.L. Rimm, A.V. Lee, Y.F. Wang, M. Pollak, L.G. Paz-Ares, D.D. KarpVolume:
7
Year:
2009
Language:
english
DOI:
10.1016/s1359-6349(09)70299-x
File:
PDF, 68 KB
english, 2009